Vascular and Endothelial Dysfunction in Progressive Supranuclear Palsy describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders.
Progressive Supranuclear Palsy (PSP) is classically considered a tauopathy characterized by neuronal loss, gliosis, and intracellular tau aggregates. However, increasing evidence suggests that vascular and endothelial dysfunction play important roles in PSP pathogenesis, potentially representing a therapeutic target.[1]
Post-mortem studies and neuroimaging have revealed blood-brain barrier (BBB) alterations in PSP:
- Increased BBB permeability: Studies using contrast-enhanced MRI have shown subtle BBB leakage in PSP patients, particularly in subcortical regions[2]
- Regional susceptibility: The brainstem and basal ganglia regions most affected in PSP show greater vascular abnormalities[1]
- Perivascular tau deposition: Tau pathology is often observed around blood vessels, suggesting a relationship between vascular dysfunction and tau spread[3]
- Endothelial tight junction alterations: Reduced expression of claudin-5, occludin, and ZO-1 in PSP brain tissue
- Matrix metalloproteinase activation: MMP-2 and MMP-9 activity degrades vascular basement membranes
- Pericyte dysfunction: Loss of pericyte coverage compromises BBB integrity
- Endothelial tau inclusions: 4R tau aggregates found in endothelial cells of PSP patients[4]
- Trans endothelial transport: Potential role of tau propagation via the glymphatic system along perivascular spaces
- Endothelial dysfunction marker: Elevated endothelin-1 in PSP CSF as a marker of endothelial activation[5]
Endothelial pathology contributes to:
- Reduced cerebral blood flow (CBF) in PSP substantia nigra and brainstem
- Impaired autoregulation
- Decreased neurovascular coupling
- Substantia nigra hypoperfusion: Early reduction in CBF in the substantia nigra, correlating with motor symptoms[6]
- Brainstem predominance: More pronounced hypoperfusion in brainstem regions compared to cortical areas
- Progression pattern: Perfusion deficits correlate with disease progression and tau burden
| Feature |
PSP |
Alzheimer's Disease |
| Primary hypoperfusion region |
Brainstem, basal ganglia |
Posterior cingulate, hippocampus |
| Timing |
Early, precedes cortical changes |
Later, follows amyloid deposition |
| BBB breakdown |
Moderate, focal |
Severe, widespread |
| Vascular tau |
Prominent (4R tau) |
Less prominent (3R/4R mix) |
- BBB-protective agents: Minocycline and other tetracyclines with anti-MMP activity
- Endothelial stabilizers: Angiotensin receptor blockers may improve endothelial function
- Vasculature modulators: L-arginine and nitric oxide modulators under investigation
- Anti-tau therapies: May reduce perivascular tau and associated vascular dysfunction
- Glymphatic enhancement: Improving perivascular clearance may reduce tau deposition
- Combination approaches: Targeting both tau pathology and vascular dysfunction
Endothelial cells form the inner lining of blood vessels and are critical for maintaining blood-brain barrier (BBB) integrity. In PSP, endothelial dysfunction contributes to disease progression through multiple mechanisms.
BBB dysfu-- Perivascular edema: Fluid accumulation around blood vessels
¶ Tau Pathology and Vascular Cells
Endothelial cells express tau protein and can accumulate pathological tau species- Hyperphosphorylated tau: Found in brain microvascular endothelial cells in PSP
- Tau secretion: Endothelial cells release tau into the circulation
- Tau phosphorylation sites: Unique patterns compared to neurons
Pericytes are critical for BBB maintenance and are affected in PSP- Impaired capillary function: Reduced cerebral blood flow
- Contribution to BBB breakdown: Pericyte-endothelial signaling disruption
The neurovascular unit includes- Pericytes:- Astrocytes: End-feet covering blood vessels
- Neurons: Regulate blood flow through neurovascular coupling
- Microglia: Immune surveillance
Key signaling in neurovascular unit dysfunction:
| Pathway |
Normal Function |
PSP Abnormality |
| VEGF |
Angiogenesis |
Dysregulated |
| Ang-1/Tie2 |
Vessel stability |
Downregulated |
| Wnt/β-catenin |
BBB development |
Impaired |
| Notch |
Vascular development |
Altered |
Reduced cerebral blood flow (CBF) is a hallmark of PSP:
- Regional reductions: Brainstem, basal ganglia, frontal cortex
- Correlation with tau: Perfusion deficits match tau pathology distribution
- Clinical significance: Correlates with disease severity
Cerebral autoregulation maintains constant CBF despite blood pressure changes:
- Blunted vasodilation: Impaired response to hypotension
- Increased rigidity: Arteriosclerosis in small vessels
- Contributes to: Ischemia and neuronal injury
- S100B: Astrocyte marker elevated with BBB disruption
- Matrix metalloproteinases (MMPs): MMP-9 indicates BBB breakdown
- Endothelial microparticles: Circulating markers of endothelial injury
- Dynamic susceptibility contrast MRI: Measures BBB permeability
- Arterial spin labeling: Quantifies cerebral blood flow
- DTI: Detects white matter vascular damage
- Tau accumulation in vessels: Cerebral amyloid angiopathy overlap
- Vascular tau deposition: Promotes inflammation
- Blood vessels as tau clearance pathway: Impaired in PSP
¶ Inflammation and Vascular Dysfunction
- Cytokine effects: TNF-α, IL-1β impair endothelial function
- Microglia-vessel interactions: Pro-inflammatory phenotypes
- Peripheral inflammation: Affects BBB integrity
¶ Vascular Biomarkers and Disease Progression
- White matter hyperintensities: Correlate with gait impairment
- BBB leakage: Associated with cognitive decline
- Cerebral hypoperfusion: Predicts disease progression
- Hypertension: Worsens outcomes in PSP
- Diabetes: Contributes to vascular dysfunction
- Smoking: Increases oxidative stress
- **Endothelial dysfun- Perfusion imaging: Disease progression tracking
Vas